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Abstract: Helix constrained polypeptides have attracted great 
interest for modulating protein-protein interactions (PPI). It is not 
known which are the most effective helix-inducing strategies for 
designing PPI agonists/antagonists. Cyclization linkers (X1-X5) were 
compared here, using circular dichroism and 2D-NMR spectroscopy, 
for α-helix induction in simple model pentapeptides, Ac-cyclo(1,5)-
[X1-Ala-Ala-Ala-X5]-NH2, in water. In this very stringent test of 
helix induction, a Lys1→Asp5 lactam linker conferred greatest α-
helicity, hydrocarbon and triazole linkers induced a mix of α- and 
310- helicity, while thio- and dithio- ether linkers produced less 
helicity. The lactam linked cyclic pentapeptide was also the most 
effective α-helix nucleator attached to a 13-residue model peptide. 
 Many biological processes are mediated by protein-protein 
interactions (PPIs), but discovering small drug-like molecules to 
target PPIs has been challenging due to the large polar interacting 
surface areas involved and only very shallow ligand-binding 
hydrophobic clefts.[1] PPIs often involve a protein α-helix[2] of 1-4 
helical turns (4-15 amino acid residues), but corresponding synthetic 
peptides of these lengths do not tend to form thermodynamically 
stable α-helix structures in water.[3] This is because water competes 
with the polar amide CO-NH components of peptide backbones for 
hydrogen bonding, whereas three backbone CO…HN hydrogen 
bonds are needed to define each turn of an α-helical peptide (Fig. 
1A). Thus, 7-10 helical turns are usually needed for a synthetic 
peptide to exhibit appreciable α-helicity in water away from a helix-
stabilizing protein environment. Methods developed to stabilize 
synthetic peptides in α-helical structures include incorporating salt 
bridges, chelating metal ion clips or covalent linkages to cyclize 
peptide segments, or attaching helix-nucleating end groups.[2c,d]  
However, there is no consensus as to which is the most effective 
strategy for inducing α-helicity in short peptides in water and 
systematic comparisons are needed. The shortest native peptide 
sequence that can theoretically form three consecutive α-helix 
defining hydrogen bonds is a pentapeptide (Fig. 1A), with the 
terminal residues being on the same helix face for sidechain-
sidechain connection to lock in an α-helical conformation. Here we 
use a cyclic pentapeptide scaffold, Ac-cyclo(1,5)-[X1-Ala-Ala-Ala-
X5]-NH2, to compare the relative effectiveness of six known 
cyclization linkers X1-X5 (Fig. 1B) reported to aid helicity in 
polypeptides. Despite their use in polypeptides, the central question 
as to which is the most effective α-helix inducer in short peptides 
has not been answered. Only one α-helical turn is possible in 
pentapeptides 1-6, which have no helicity in water when uncyclized, 

























Figure 1. A) Three consecutive hydrogen bonds define an α-helix stabilized by 
linking sidechains at positions 1 and 5. B) Cyclic pentapeptides 1-6. (* denotes 
isomers: triazole 3a: L-, 3b: D- at X5; thioether 6a,6b:  L- or D- at X1, see SI). 
Compounds 1-6 all have three alanines, known to favor α-helicity, 
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between their different linkers at positions 1 and 5. Compound 1 incorporates 
a sidechain to sidechain lactam linker, which is a helix inducer in 
polypeptides,[3,4] hormones (PTH[5], GLP-1[6], nociception[7]), PPI inhibitors 
(HIV[8], RSV[9] viral fusion) and others[10] and in short peptides in water.[11] 
The position of the amide bond in the linker of 1 is known to be crucial for 
optimal helicity, other lactam crosslinks showing partial or no α-helicity.[11b] 
Compound 2 was formed by a ring-closing metathesis cyclization[12] using 
α,α-disubstituted amino acids with olefin tethers.[13] Such a crosslinking 
strategy has been used[14] for example to design helices that promote BCL2 
apoptosis[14a] or inhibit HIV-1 capsid assembly[14b] or NOTCH 
transcription.14c The α-methyl groups in the linker in 2 reportedly assist helix 
stabilization, although may be not be essential.[14l] Compound 3 was made by 
Cu(I)-mediated Huisgen 1,3-dipolar cycloaddition (click reaction)[15] of azido 
norleucine and L- or D-propargylglycine (Pra) at i and i+4 positions, and this 
has been applied to biological targets like PTH[15a] and ß-catenin/BCL9.[15c] 
Compounds 4 and 5 were cyclized by reacting cysteine side chains with 
dibromo-m-xylene[16] or perfluoroaryl crosslinkers, respectively.[17] The 
thioether in 6, not known as a helix constraint, was compared as it has no 
polar or ring linker atoms. Based on uses in polypeptides,[11,13,15] the linkers 
in Figure 1B represent the best reported helix-inducing connectivity with 
optimized linker size (6-, 7-, 8-, 9-atom bridges), positioning of heteroatoms, 
rings or double bonds, and cycle-forming D/L- amino acids.  
Linear peptide precursors to 1-6 were synthesized by standard Fmoc 
solid-phase peptide synthesis protocols and cyclized to 1-6 by reported 
procedures (Supp. Info., SI). Circular dichroism spectra (Fig. 
2A) recorded in phosphate buffer (pH 7.2, 298K) are typically used[18a] to 
quantitate relative % helicity (Figure S1, SI), based on molar elipticity at λ = 
222 nm in polypeptides (but ~215 nm in short peptides[11]). The Lys1-Asp5 
lactam crosslinked peptide 1 showed strong α-helicity in water, with two 
symmetrical minima peaks at 207 and 215 nm (ratio 1.0: 1.1) and a positive 
maximum at 190 nm. Relative to 1 (100% α-helicity), hydrocarbon 2 and 
triazole 3a had reduced helicity (62%) and slightly shifted minima (203 : 217 
nm; 1.0 : 0.8) consistent with less α-helical structure than 1. The triazole 
linker afforded more helicity when formed from click cyclization of L-Pra at 
position 1 (3a, 62%) than D-Pra (3b, 48%). Thioether-bridged peptides 4-6 
were much less helical and less structured, with weak elipticity at λ ~215-





Figure 2. CD spectra of crosslinked pentapeptides: KD lactam 1 (black), 
hydrocarbon 2 (red), triazole 3a (blue), m-xylene thioether 4 (orange), 
perfluorobenzyl 5 (violet) and alkyl thioether 6a (green) at 298 K in: A) 10 mM 
phosphate buffer pH 7.2 or B) 50% TFE/10mM phosphate buffer pH 7.2. 
To identify any further capacity for helix induction in 1-6, CD spectra 
were also measured after adding the helix-promoting solvent, 2,2,2-
trifluoroethanol (TFE) (Fig. 2B). The CD spectrum for 1 did not change on 
adding TFE, indicating maximal helicity. However, α-helicity (based on 
[θ]215) increased for 2 and 3a from 62% to 75% (50% TFE). Of thioether 
linkers 4-6, both 4 (35% to 98%) and 6a (3% to 74%) became more helical 
in 50% TFE.  
Linkers in 1-6 are reportedly the best of their kinds for inducing 
helicity in polypeptides, but there are 7 atoms in the linker in 1 versus 8 
atoms in 2 and 3a. To investigate if shortening the linker in 2 or 3 to a 7-
atom bridge might increase helix stabilization in water, we prepared 
analogues (Fig. 3) with 7-membered hydrocarbon (2a,b) or triazole (3c,d) 
crosslinks. Compared to the 8-carbon linker in 2, a 7-carbon linker induced 
similar helicity when the cis-alkene bond was at C4-C5 positions (2b, Fig. 
3A), but no helicity when at C3-C4 (peptide 2a) or C2-C3.[13a] Shortening the 
triazole linker in 3a to a 7-atom bridge (3c, 3d) was detrimental to helicity 
here (Figure 3B), and in longer peptides reported.[15c] Thus, helicity was very 
sensitive to the location of the constraint in the linker, as also reported for 
lactam linked analogues of 1.[11] This is likely due to some precision needed 


















Figure 3. Cyclic pentapeptides with a 7-atom hydrocarbon (A) or triazole (B) 
linker and their CD spectra (10 mM phosphate buffer, pH 7.2, 298 K). 
Using 1H NMR spectroscopy, three dimensional solution 
structures were determined for 1 and 3a (90% H2O:10% D2O) and 2 
(40% H2O:10% D2O, 50% CD3CN). We have previously reported 
some structural data for 1 and close analogues.[10a,11] All the peptides 
1, 2 and 3a showed some low amide coupling constants, 3JNHCHα< 6 
Hz (Fig. 4; Table S1, SI) consistent with some helical structure.[18b] 
For 1 and 3a, all but Asp5 (1) and X5 (3a) coupling constants were 
< 6 Hz, consistent with helicity. For 2, Ala3 and Ala4 had 3JNHCHα > 
6 Hz, indicating less helicity, consistent with CD spectra. Three 
consecutive low amide NH temperature coefficients (Fig. S2, S3, 
S4; Table S1, SI) for 1, 2 and 3a were consistent with three 
consecutive hydrogen bonds. In addition, the ROESY spectrum for 
1, 2 and 3a showed some αN(i,i+2), αN(i,i+3) and αN(i,i+4) ROE 
signals indicative of helical structures (Fig. 4). However, αN(i,i+3) 
and αN(i,i+4) ROE intensities were stronger and more numerous for 
peptide 1 than 2 and 3a, which had more αN(i,i+2) than for 1. This 
suggested more α-helical structure in 1 than 2 and 3a, and some 310-
helicity in 2 and 3a. NMR-derived solution structures for 1 (Fig. 4) 
showed a single α-helical turn with RSMD 3.360 Å versus an 
idealized α-helix, while 2 and 3a had RMSD 3.375 Å and 3.365 Å, 
respectively. The Cα-Cα distance between first and fifth residues in 



















































































































































 Figure 4. A) 
Superimposition of 20 
lowest energy structures 
for cyclic pentapeptides 1, 
2 and 3a calculated by 
NMR at 298 K. Average 
backbone RMSD for 
structure ensemble was 
0.37, 0.49 and 0.32 Å, 
respectively. B) ROE 
summary diagram for 1, 2 
and 3a showing distance 
restraints used to 
calculate the peptide 
structure. Bar thickness 
reflects the intensity of 
the ROE cross peaks. 
Asterisk indicates 
absence of coupling 
constant due to presence 





to the corresponding distance in an idealized α-helix (5.51 Å, ϕ = 
-57°; ψ = -47°) and 310-helix (8.30 Å, ϕ = -50°; ψ = -28°). This 
indicated slightly more elongated (mix with 310-) helical 
structures in 2 and 3a, than the more compact α-helix in 1, 
consistent with CD spectra. This is also supported by 
Ramachandran[18c] plots (Fig. 5) obtained from the peptide 
structures (Fig. 4). Only for lactam 1 did all (ϕ, ψ) angles occupy 
space corresponding to α-helicity in the plot, whereas peptides 2 
and 3a both had several angles located outside of the 
Ramachandran space that defines α-helicity. 












Figure 5. Ramachandran plots of (ϕ, ψ) angles derived from the average of 
the 20 lowest energy NMR-derived solution structures calculated for 1 
(black), 2 (red) and 3 (blue). Only those for 1 are entirely in α-helix space. 
Solid line encloses a region allowed with full radii, dashed lines enclose 
regions allowed with smaller radii from hard-sphere calculations.[18c] 
       The unique presence of an amide bond in the linker of 1 
potentially allows additional H-bonding to the backbone, which 
might account for greater α-helicity in 1. However, the 
temperature dependence of the chemical shift for the linker 
amide NH in 1 (Δδ/T ∼9.3 Hz) was much higher than is 
characteristic of a hydrogen bond (Δδ/T ≤ 4 Hz).[18d] Moreover, 
when the amide NH was replaced by a lactone O (1a) or amide 
NMe (1c) (Fig. 6), the molar elipticity (θ215) was unchanged, 
indicating no effect of removing the amide NH on α-helicity. 
Although molar elipticity was unchanged at θ215, the CD 
spectrum for lactone 1a differs from lactam 1 by an increase in 
the π-π* band at 204 nm and reduced intensity of the 190 nm 
band, which indicates a slight relaxation of the helical structure, 
consistent with more 310-helix in the mix. The molar elipticity 
[θ]215 was similarly unchanged when the linker amide NH 
became NMe (1b vs 1c, Figure 6), consistent with the linker NH 
not forming a hydrogen bond to the backbone. We used Ac-
cyclo(1,5)-[KLLLD]-NH2 (1b) to check the effect of N-













Figure 6. Lactone (1a) and lactam (1b, 1c) linked cyclic peptide analogues 
of 1 and comparative CD spectra (10 mM phosphate buffer, pH 7.2, 298 K).  
Having established the rank order of α-helix induction of 
these linkers in the shortest possible alanine-containing peptide 
helix, we tested the relative capacities of linkers to nucleate α-
helicity in a longer peptide sequence. A series of 18mer peptides, 
Ac-AARAARAARAARA-[X14ARAX18]-NH2 (Ala and Arg 
residues used to aid peptide helicity and solubilization in water), 
was prepared and their CD spectra were examined in aqueous 
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increased helicity (92%; 50% and 51% respectively) when 











Figure 7. CD spectra of Ac-AARAARAARAARA (50 µM) attached to 
AARAA-NH2 (7, dots), lactam 1 (8, black), hydrocarbon 2 (9, red) and 
triazole 3a (10, blue) in 50 mM phosphate buffer (pH 7.2, 298K). 
In conclusion, the Lys1→Asp5 lactam-bridge was the most 
effective crosslink in these cyclic pentapeptides at inducing α-
helicity in water, producing the smallest and most compact 
helical structure for 1. Hydrocarbon (in 2) and triazole (in 3) 
1→5 crosslinks were also able to induce some helicity in water, 
but their structures were conformationally more flexible and less 
α-helical, as evidenced by CD and NMR spectroscopic studies. 
The linkers in 2 and 3 induced looser, slightly more elongated, 
helical structures in their conformational ensemble mix. This is 
not to say that 2 and 3 will be ineffective helix nucleators within 
longer peptides, but were assessed here under very demanding 
conditions in an otherwise non-helical 5-residue peptide and as 
helix nucleators attached to the end of a model 13-mer peptide 
with little helicity in water. In longer bioactive peptides already 
possessing some helicity in water, each of these linkers may be 
satisfactory for an intended use either because they aid helix 
formation or because they enable access to other non-alpha 
helical structures due to their inherent flexibility. However, in the 
very short peptides studied here, 1 was the most α-helical cyclic 
pentapeptide in water and also the most effective helix nucleator 
attached to a model 13-mer peptide. These findings may enable 
optimal selection of helix-constraining linkers in short peptides. 
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Pentapeptides in Water ** 
 
Covalent linkers between amino acid sidechains in peptide sequences can induce 
bioactive α−helical conformations that modulate protein-protein interactions. A 
lactam linker is shown here to confer greatest α-helicity in water to a cyclic 
pentapeptide, forming a near idealized one-turn α-helix, while other crosslinks 
induced a mix of α- and 310- helicity or negligible helicity. The lactam-linked cyclic 
pentapeptide was also the most effective α-helix nucleator when attached to a 13-
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Alloc,	  allyloxyxarbonyl;	  DBU,	  1,8-­‐Diazabicyclo[5.4.0]undec-­‐7-­‐ene;	  DIPEA,	  diisopropylethylamine;	  DMAP,	  4-­‐
dimethylaminopyridine;	  DMF,	  dimethylformamide;	  ESI-­‐MS,	  electrospray	  ionization	  mass	  spectrometry;	  Fmoc,	  9-­‐
fluorenylmethyloxycarbonyl;	  HBTU,	  2-­‐(1H-­‐benzotriazol-­‐1-­‐yl)-­‐1,1,3,3-­‐tetramethyl	  uronium	  hexafluorophosphate:	  HCTU,	  2-­‐
(1H-­‐6-­‐chlorobenzotriazol-­‐1-­‐yl)-­‐1,1,3,3-­‐tetramethyl	  uronium	  hexafluorophosphate;	  HR-­‐MS,	  High-­‐resolution	  mass	  
spectroscopy;	  MBHA,	  4-­‐methyl-­‐benzylhydrylamine;	  Mmt,	  4-­‐methoxyltrityl;	  MTBD,	  7-­‐methyl-­‐1,5,7-­‐triazabicyclo[4.4.0]dec-­‐5-­‐
ene;	  Mtt,	  4-­‐methyltrityl;	  NBS,	  nitrobenzenesulfonyl; PyBOP,	  benzotriazol-­‐1-­‐yl-­‐oxytripyrrolidinophosphonium	  
hexafluorophosphate;	  RP-­‐HPLC,	  reserved-­‐phase	  high	  performance	  liquid	  chromatography;	  RP-­‐HPLC;	  UHPLC,	  reserved-­‐phase	  
ultra	  high	  performance	  liquid	  chromatography;	  OPip,	  phenyl	  isopropyl	  ester;	  RT,	  room	  temperature;	  SPPS,	  solid-­‐phase	  




All	  solvents	  and	  reagents	  used	  during	  peptide	  chain	  assembly	  were	  peptide	  synthesis	  grade	  and	  purchased	  from	  commercial	  
suppliers	  unless	  otherwise	  stated.	  	  
	  
General	  manual	  SPPS	  of	  the	  pentapetide	  linear	  precursors	  
Short	  pentapeptides	  were	  prepared	  by	  standard	  manual	  Fmoc	  solid-­‐phase	  synthesis	  using	  HBTU	  as	  coupling	  reagent	  and	  Rink	  
Amide	  MBHA	  resin.1	  A	  4-­‐fold	  excess	  of	  the	  respective	  protected	  amino	  acid	  was	  activated	  using	  HBTU	  (4	  equiv)	  and	  DIPEA	  (4	  
equiv)	  in	  DMF	  and	  coupled	  to	  the	  resin	  for	  10	  minutes.	  Fmoc	  deprotections	  were	  achieved	  by	  2	  ×	  1	  min	  treatments	  with	  
excess	  (1:1)	  piperidine:DMF.	  Coupling	  yields	  were	  monitored	  by	  ninhydrin	  test.	  The	  N-­‐terminus	  was	  acetylated	  with	  
Ac2O:DIPEA:DMF	  (0.87:0.47:15	  mL)	  for	  10	  minutes.	  	  
	  
General	  automated	  SPPS	  for	  the	  synthesis	  of	  the	  longer	  peptides	  
Peptides	  7-­‐10	  were	  assembled	  on	  a	  peptide	  synthetizer	  (Symphony)	  using	  Rink	  Amide	  MBHA	  resin.	  5	  equiv.	  of	  Fmoc-­‐
protected	  amino	  acid,	  5	  equiv.	  of	  HCTU	  and	  5	  equiv.	  of	  DIPEA	  were	  used	  in	  2	  x	  15min	  coupling	  cycles.	  Fmoc	  deprotections	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were	  achieved	  by	  2	  ×	  3	  min	  treatments	  with	  excess	  2:1	  piperidine:DMF.	  The	  N-­‐terminus	  was	  acetylated	  with	  Ac2O:DIPEA	  
(2:1)	  in	  DMF	  for	  10	  minutes	  Details	  on	  the	  C-­‐terminal	  cyclization	  is	  described	  for	  each	  individual	  peptide	  in	  the	  next	  pages.	  
	  
Cleavage	  from	  solid	  support	  and	  peptide	  purification	  
Peptides	  were	  cleaved	  from	  the	  resin	  by	  treatment	  with	  TFA:TIS:H2O	  (95:2.5:2.5)	  for	  2	  h.	  The	  crude	  peptides	  were	  
precipitated	  and	  washed	  with	  cold	  Et2O,	  redissolved	  in	  50%	  acetonitrile/0.05%	  TFA	  in	  water	  and	  lyophylised.	  Peptides	  were	  
purified	  by	  RP-­‐HPLC	  using	  a	  Phenomenex	  Luna	  C18	  column	  eluting	  at	  a	  flow	  rate	  of	  20	  mL/min	  and	  a	  gradient	  of	  0	  to	  50%	  
buffer	  B	  (90%	  CH3CN/10%	  H2O/0.1%	  TFA	  in	  buffer	  A,	  0.1%	  TFA	  in	  water)	  over	  30	  minutes.	  
	  
Analytical	  methods	  
Analytical	  RP-­‐HPLC	  was	  performed	  on	  an	  Agilent	  system,	  using	  a	  Phenomenex	  Luna	  C18	  5	  um	  (250	  x	  4.60	  mm)	  column	  eluting	  
at	  flow	  rate	  of	  1	  mL/min	  and	  gradient	  0	  to	  (x)	  %	  buffer	  B	  (90%	  CH3CN/10%	  H2O/0.1%	  TFA	  in	  buffer	  A,	  0.1%	  TFA	  in	  water)	  over	  
20	  minutes.	  Analytical	  UHPLC	  was	  performed	  on	  a	  Shimadzu	  Nexre	  using	  Agilent	  Zorbax	  R-­‐ODS	  III	  column	  2.0	  mm	  i.d	  x	  75	  mm	  
1.6	  mm).	  High-­‐resolution	  mass	  spectroscopy	  was	  conducted	  on	  an	  Applied	  Biosystems	  QSTAR	  Elite	  time-­‐of-­‐flight	  
spectrometer.	  
	  
Lactam	  cyclopentapeptide	  Ac-­‐(1,5)-­‐[KAAAD]-­‐NH2	  (1)	  
Fmoc-­‐Lys(Mtt)-­‐OH	  and	  Fmoc-­‐Asp(OPip)-­‐OH	  were	  employed	  for	  incorporation	  of	  non-­‐standard	  
amino	  acids	  at	  positions	  1	  and	  5	  respectively.1	  The	  peptide	  Ac-­‐Lys(Mtt)-­‐Ala-­‐Ala-­‐Ala-­‐Asp(OPip)	  
was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  The	  resin	  was	  then	  
washed	  with	  DCM	  and	  treated	  repeatedly	  with	  2%	  TFA	  in	  DCM	  (5	  x	  2	  min).	  After	  washing	  with	  
DMF,	  a	  solution	  of	  PyBOP	  (4	  equiv)	  and	  DIPEA	  (4	  equiv)	  in	  DMF	  was	  added	  to	  the	  resin	  and	  the	  
reaction	  was	  agitated	  overnight.	  Subsequently,	  the	  peptide	  was	  cleaved	  by	  TFA	  acidolysis	  and	  
purified	  by	  RP-­‐HPLC.	  Analytical	  data	  identical	  to	  that	  previously	  reported.1	  
	  
Lactone	  cyclopentapeptide	  (1a)	  
Boc-­‐L-­‐6-­‐hydroxynorleucine	  and	  Fmoc-­‐Asp(OPip)-­‐OH	  were	  employed	  for	  incorporation	  of	  non-­‐
standard	  amino	  acids	  at	  positions	  1	  and	  5	  respectively.	  The	  peptide	  Boc-­‐(6-­‐hydroxynorleucine)-­‐
Ala-­‐Ala-­‐Ala-­‐Asp(OPip)	  was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  
The	  cyclization	  step	  was	  carried	  out	  as	  follow:	  first,	  the	  resin	  was	  treated	  with	  2%	  TFA	  in	  DCM	  
(10	  x	  2	  min),	  washed	  with	  DMF	  and	  then	  a	  solution	  of	  PyBOP	  (2	  equiv),	  DMAP	  (1	  equiv)	  and	  
DIPEA	  (1	  equiv)	  in	  DMF	  was	  added	  to	  the	  resin	  and	  the	  reaction	  was	  stirred	  overnight.	  The	  cyclic	  
peptide	  was	  cleaved	  by	  TFA	  acidolysis	  and	  the	  crude	  material	  was	  isolated	  after	  precipation	  with	  
diethylether.	  The	  crude	  was	  dissolved	  in	  a	  minimal	  of	  DMF	  and	  the	  N-­‐terminal	  acetylated	  with	  Ac2O	  (4	  equiv)	  and	  DIPEA	  (4	  
equiv)	  for	  30	  min.	  The	  solvent	  was	  removed	  in	  high	  vacuum	  and	  the	  resulting	  solid	  was	  redissolved	  in	  acetonitrile.	  The	  final	  
product	  was	  purified	  by	  RP-­‐HPLC.	  	  
Analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  30%	  B	  over	  20	  min,	  Rt	  =	  14.2	  min.	  HR-­‐MS	  for	  [M+H]
+:	  	  499.2511;	  (calculated	  for	  
1a:	  499.2511).	  	  
	  
Lactam	  cyclopentapeptide	  Ac-­‐(1,5)-­‐[KLLLD]-­‐NH2	  (1b)	  
Fmoc-­‐Lys(Mtt)-­‐OH	  and	  Fmoc-­‐Asp(OPip)-­‐OH	  were	  employed	  for	  incorporation	  of	  non-­‐
standard	  amino	  acids	  at	  positions	  1	  and	  5	  respectively.1	  The	  peptide	  Ac-­‐Lys(Mtt)-­‐Leu-­‐Leu-­‐
Leu-­‐Asp(OPip)	  was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  
The	  resin	  was	  then	  washed	  with	  DCM	  and	  treated	  repeatedly	  with	  2%	  TFA	  in	  DCM	  (5	  x	  2	  
min).	  After	  washing	  with	  DMF,	  a	  solution	  of	  PyBOP	  (4	  equiv)	  and	  DIPEA	  (4	  equiv)	  in	  DMF	  
was	  added	  to	  the	  resin	  and	  the	  reaction	  was	  agitated	  overnight.	  Subsequently,	  the	  peptide	  
was	  cleaved	  by	  TFA	  acidolysis	  and	  purified	  by	  RP-­‐HPLC.	  	  
Analytical	  UHPLC:	  linear	  gradient	  from	  0%	  to	  100%	  B	  over	  6	  min,	  Rt	  =	  3.6	  min.	  HR-­‐MS	  for	  [M+H]
+:	  	  624.4075;	  (calculated	  for	  














































Lactam	  cyclopentapeptide	  Ac-­‐(1,5)-­‐[K(ε-­‐NMe)LLLD]-­‐NH2	  (1c)	  
Fmoc-­‐Lys(Alloc)-­‐OH	  and	  Fmoc-­‐Asp(OPip)-­‐OH	  were	  employed	  for	  incorporation	  of	  non-­‐
standard	  amino	  acids	  at	  positions	  1	  and	  5	  respectively.	  The	  peptide	  Ac-­‐Lys(Alloc)-­‐Leu-­‐Leu-­‐
Leu-­‐Asp(OPip)	  was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  
The	  Alloc	  protecting	  group	  was	  removed	  by	  treating	  the	  resin	  with	  a	  solution	  of	  phenylsilane	  
(24	  equiv)	  and	  Pd(PPh3)4	  (0.1	  equiv).	  N2	  was	  bubbled	  through	  the	  reaction	  mixture	  for	  10	  
min	  and	  the	  resin	  was	  washed	  with	  DCM.	  A	  solution	  of	  2-­‐	  nitrobenzenesulfonyl	  
chloride	  (4	  equiv)	  and	  DIPEA	  (4	  equiv)	  in	  DCM	  was	  added	  to	  the	  resin-­‐bound	  free-­‐amine	  
peptide	  and	  shaken	  for	  30	  min.	  The	  resin	  was	  filtered	  and	  washed	  with	  DCM	  and	  DMF.	  The	  N-­‐methylation	  procedure	  was	  
conducted	  by	  treatment	  with	  a	  solution	  of	  methyl	  iodide	  (4	  equiv)	  and	  MTBD	  (6	  equiv),	  and	  the	  reaction	  was	  agitated	  
overnight.	  For	  subsequent	  o-­‐NBS	  deprotection,	  the	  peptide	  was	  treated	  with	  a	  solution	  of	  mercaptoethanol	  (10	  equiv)	  and	  
DBU	  (3	  equiv)	  in	  DMF	  for	  5	  min.	  The	  deprotection	  procedure	  was	  repeated	  and	  the	  resin	  washed	  with	  DMF	  (5x).	  The	  resin	  
was	  then	  washed	  with	  DCM	  and	  treated	  repeatedly	  with	  2%	  TFA	  in	  DCM	  (5	  x	  2	  min).	  Subsequently,	  the	  peptide	  was	  cleaved	  
by	  TFA	  acidolysis	  to	  afford	  the	  crude	  linear	  peptide.	  The	  linear	  peptide	  was	  then	  treated	  with	  a	  solution	  of	  PyBOP	  (4	  equiv)	  
and	  DIPEA	  (4	  equiv)	  in	  DMF,	  with	  overnight	  stirring.	  The	  reaction	  mixture	  was	  reduced	  in	  vacuum	  and	  the	  crude	  cyclized	  
peptide	  was	  redissolved	  in	  50%	  acetonitrile	  in	  H2O	  and	  purified	  by	  RP-­‐HPLC.	  
Analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  100%	  B	  over	  30	  min,	  Rt	  =	  18.6	  min.	  HR-­‐MS	  for	  [M+H]
+:	  638.4238	  (calculated	  
638.4236).	  
	  
Hydrocarbon	  stapled	  cyclopentapeptide	  (2)	  
Fmoc-­‐(S)-­‐2-­‐(4-­‐pentenyl)alanine	  (Fmoc-­‐X-­‐OH)	  was	  employed	  for	  incorporation	  of	  non-­‐standard	  
amino	  acids	  at	  positions	  1	  and	  5.	  The	  peptide	  Ac-­‐X-­‐Ala-­‐Ala-­‐Ala-­‐X	  was	  assembled	  on	  the	  solid	  
support	  as	  described	  in	  the	  general	  procedure.	  The	  peptide	  was	  cleaved	  from	  the	  resin	  and,	  
after	  freeze-­‐drying,	  submitted	  to	  cyclization.	  The	  ring-­‐closing	  metathesis	  was	  performed	  by	  
dissolving	  the	  crude	  peptide	  (23mg,	  0.0437mmol)	  in	  DCM	  (55	  mL),	  followed	  by	  addition	  of	  
Grubb’s	  catalyst	  1st	  generation	  (22mg)	  under	  argon.2	  After	  5	  h,	  the	  reaction	  mixture	  was	  
concentrated	  in	  vacuum	  and	  the	  crude	  peptide	  was	  redissolved	  in	  50%	  acetonitrile	  in	  H2O	  and	  
purified	  by	  RP-­‐HPLC.	  	  
Analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  50%	  B	  over	  20	  min,	  Rt	  =19.6	  min.	  HR-­‐MS	  for	  [M+H]
+:	  
523.3241	  (calculated	  for	  C25H43N6O6:	  523.3239).	  
	  
Hydrocarbon	  stapled	  cyclopentapeptide	  (2a)	  	  
Fmoc-­‐(S)-­‐2-­‐(4-­‐butenyl)alanine	  (Fmoc-­‐Z-­‐OH)	  was	  employed	  for	  incorporation	  of	  non-­‐standard	  
amino	  acids	  at	  position	  1	  and	  Fmoc-­‐(S)-­‐2-­‐(4-­‐pentenyl)alanine	  (Fmoc-­‐Y-­‐OH)	  was	  employed	  for	  
incorporation	  of	  non-­‐standard	  amino	  acids	  at	  position	  5.	  The	  peptide	  Ac-­‐Z-­‐Ala-­‐Ala-­‐Ala-­‐Y	  was	  
assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  RCM	  cyclization	  and	  final	  
purification	  was	  performed	  as	  described	  for	  peptide	  2.	  	  
For	  2a,	  analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  50%	  B	  over	  20	  min,	  Rt	  =18.1	  min.	  HR-­‐MS	  for	  
[M+H]+:	  509.3081	  (calculated	  for	  C24H41N6O6:	  509.3082).	  
	  
Hydrocarbon	  stapled	  cyclopentapeptide	  (2b)	  
Fmoc-­‐(S)-­‐2-­‐(4-­‐pentenyl)alanine	  (Fmoc-­‐Y-­‐OH)	  was	  employed	  for	  incorporation	  of	  non-­‐standard	  
amino	  acids	  at	  position	  1	  and	  Fmoc-­‐(S)-­‐2-­‐(4-­‐butenyl)alanine	  (Fmoc-­‐Z-­‐OH)	  was	  employed	  for	  
incorporation	  of	  non-­‐standard	  amino	  acids	  at	  position	  5.	  The	  peptide	  Ac-­‐Y-­‐Ala-­‐Ala-­‐Ala-­‐Z	  was	  
assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  RCM	  cyclization	  and	  final	  
purification	  was	  performed	  as	  described	  for	  peptide	  2.	  	  


















































[M+H]+:	  509.3081	  (calculated	  for	  C24H41N6O6:	  509.3082).	  
	  
Triazole	  stapled	  cyclopentapeptide	  (3a	  and	  3b)	  
Fmoc-­‐Lys(N3)-­‐OH	  (Fmoc-­‐azidolysine)	  and	  Fmoc-­‐Pra-­‐OH	  
(Fmoc-­‐L-­‐propargylglycine	  for	  3a;	  Fmoc-­‐D-­‐propargylglycine	  
for	  3b)	  were	  employed	  for	  incorporation	  of	  non-­‐standard	  
amino	  acids	  at	  positions	  1	  and	  5	  respectively.	  The	  peptide	  
Ac-­‐Lys(N3)-­‐Ala-­‐Ala-­‐Ala-­‐Pra	  was	  assembled	  on	  the	  solid	  
support	  as	  described	  in	  the	  general	  procedure.	  The	  
peptide	  was	  cleaved	  from	  the	  resin	  and,	  after	  freeze-­‐drying,	  submitted	  to	  cyclization.	  The	  crude	  linear	  peptide	  (24mg,	  
0.046mmol)	  was	  dissolved	  in	  a	  solution	  of	  H20:tBuOH	  (2:1,	  180	  mL)	  containing	  CuSO4.5H2O	  (120mg).
3	  Sodium	  ascorbate	  
(96mg)	  was	  added,	  the	  reaction	  mixture	  was	  stirred	  for	  15	  minutes,	  and	  finally	  quenched	  by	  addition	  of	  TFA	  until	  the	  solution	  
was	  clear.	  The	  resulting	  solution	  was	  lyophilised	  and	  the	  cyclic	  product	  was	  purified	  by	  RP-­‐HPLC.	  
Analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  35%	  B	  over	  20	  min,	  Rt	  =	  15.0	  min	  (3a);	  14.9	  min	  (3b).	  HR-­‐MS	  for	  [M+H]
+	  for	  3a:	  
522.2783	  (calculated	  for	  C22H36N9O6:	  522.2783);	  [M+H]
+	  for	  3b:	  522.2783	  (calculated	  for	  C22H36N9O6:	  522.2783).	  	  
	  
Triazole	  stapled	  cyclopentapeptide	  (3c)	  	  	  
Fmoc-­‐Orn(N3)-­‐OH	  (Fmoc-­‐azido-­‐ornithine)	  and	  Fmoc-­‐Pra-­‐OH	  were	  employed	  for	  incorporation	  of	  
non-­‐standard	  amino	  acids	  at	  positions	  1	  and	  5	  respectively.	  The	  peptide	  Ac-­‐Orn(N3)-­‐Ala-­‐Ala-­‐Ala-­‐Pra	  
was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  Cu-­‐catalyzed	  click	  
cyclization	  and	  final	  purification	  was	  performed	  as	  described	  for	  peptide	  3a.	  	  
For	  3a,	  analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  50%	  B	  over	  20	  min,	  Rt	  =	  9.5	  min.	  HR-­‐MS	  for	  
[M+H]+:	  508.2628	  (calculated	  for	  C21H34N9O6:	  508.2627).	  
	  
Triazole	  stapled	  cyclopentapeptide	  (3d)	  
Fmoc-­‐Pra-­‐OH	  and	  Fmoc-­‐Orn(N3)-­‐OH	  (Fmoc-­‐azido-­‐ornithine)	  were	  employed	  for	  incorporation	  of	  
non-­‐standard	  amino	  acids	  at	  positions	  1	  and	  5	  respectively.	  The	  peptide	  Ac-­‐Pra-­‐Ala-­‐Ala-­‐Ala-­‐
Orn(N3)	  was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  Cu-­‐catalyzed	  
click	  cyclization	  and	  final	  purification	  was	  performed	  as	  described	  for	  peptide	  3a.	  	  
For	  3b,	  analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  50%	  B	  over	  20	  min,	  Rt	  =	  10.0	  min.	  HR-­‐MS	  for	  




m-­‐Xylene	  bridged	  cyclopentapeptide	  (4)	  
Fmoc-­‐Cys(Mmt)-­‐OH	  was	  used	  for	  the	  incorporation	  of	  cysteines	  at	  positions	  1	  and	  5.	  The	  linear	  
peptide	  Ac-­‐Cys(Mmt)-­‐Ala-­‐Ala-­‐Ala-­‐Cys(Mmt)	  was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  
general	  procedure.	  The	  resin	  was	  then	  washed	  with	  DCM	  and	  the	  Mmt	  protecting	  group	  was	  
removed	  by	  treating	  the	  resin	  1%	  TFA	  in	  DCM	  for	  15	  min.	  On-­‐resin	  cyclization	  was	  conducted	  with	  
α,α’-­‐dibromo-­‐m-­‐xylene	  (2	  eq)	  and	  DIPEA	  (4	  eq)	  in	  DMF	  for	  3	  h	  at	  room	  temperature.4	  Subsequently,	  
the	  peptide	  was	  cleaved	  by	  TFA	  acidolysis	  and	  purified	  by	  RP-­‐HPLC.	  	  
Analytical	  UHPLC:	  linear	  gradient	  from	  0%	  to	  100%	  B	  over	  6	  min,	  Rt	  =	  4.5	  min.	  HR-­‐MS	  for	  [M+H]
+:	  
581.2211	  (calculated	  for	  C25H37N6O6S2:	  581.2211)	  
	  
Tetrafluorobenzyl	  bridged	  cyclopentapeptide	  (5)	  
Fmoc-­‐Cys(Mmt)-­‐OH	  was	  used	  for	  the	  incorporation	  of	  cysteines	  at	  positions	  1	  and	  5.	  The	  linear	  peptide	  Ac-­‐Cys(Mmt)-­‐Ala-­‐Ala-­‐
Ala-­‐Cys(Mmt)	  was	  assembled	  on	  the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  The	  resin	  was	  then	  washed	  with	  









































































conducted	  with	  1,4-­‐dibromo-­‐2,3,5,6-­‐tetrafluorobenzene	  (2	  eq)	  and	  DIPEA	  (4	  eq)	  in	  DMF	  for	  3	  h	  at	  
room	  temperature.	  Subsequently,	  the	  peptide	  was	  cleaved	  by	  TFA	  acidolysis	  and	  purified	  by	  RP-­‐
HPLC.	  	  




Thioether	  bridged	  cyclopentapeptide	  (6a	  and	  6b)	  
The	  amino	  acid	  2-­‐acetamido-­‐6-­‐bromohexanoic	  acid	  was	  synthesized	  accordingly	  with	  a	  
procedure	  reported	  in	  the	  literature5	  as	  a	  racemic	  mixture	  of	  D-­‐	  and	  L-­‐	  isomers.	  The	  racemic	  
amino	  acid	  was	  used	  for	  the	  incorporation	  of	  non-­‐standard	  residue	  at	  position	  1.	  Fmoc-­‐Cys(Trt)-­‐
OH	  was	  used	  for	  incorporation	  of	  cysteine	  at	  position	  5.	  The	  linear	  peptide	  was	  assembled	  on	  
the	  solid	  support	  as	  described	  in	  the	  general	  procedure.	  The	  peptide	  was	  cleaved	  from	  the	  resin	  
and	  purified	  by	  HPLC	  to	  give	  two	  separable	  diastereoisomers.	  Each	  of	  these	  isomers	  was	  
submitted	  to	  cyclization.	  The	  pure	  linear	  peptide	  (50mg,	  0.086mmol)	  was	  dissolved	  in	  50%	  acetonitrile	  (100mL)	  and	  the	  
resulting	  solution	  was	  diluted	  in	  0.1	  M	  sodium	  phosphate	  pH	  9	  (350	  mL).	  After	  stirring	  for	  4	  hours	  at	  room	  temperature,	  the	  
reaction	  was	  acidified	  by	  addition	  of	  TFA,	  diluted	  twice	  with	  water	  and	  purified	  by	  RP-­‐HPLC.	  The	  two	  resulting	  thioether	  cyclic	  
products	  6a	  and	  6b	  were	  analyzed	  as	  cyclic	  thioethers.	  Compound	  6a	  was	  the	  first	  eluting	  peptide	  during	  HPLC	  analysis.	  
Because	  both	  compounds	  showed	  no	  relevant	  helical	  conformation	  in	  water	  accordingly	  to	  CD	  analysis	  (Figure	  S1),	  we	  were	  
not	  persuaded	  to	  carry	  on	  any	  further	  determination	  of	  the	  stereochemistry	  in	  position	  1.	  
Analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  50%	  B	  over	  20	  min,	  Rt	  =13.4	  min	  (6a);	  0%	  to	  35%	  B	  over	  20	  min,	  Rt	  =18.9	  min	  (6b).	  
HR-­‐MS:	  [M+H]+	  for	  6a:	  501.2491	  (calculated	  for	  C21H37N6O6S:	  501.2490);	  [M+H]




Linear	  peptide	  assembled	  on	  Symphony	  synthesizer,	  cleaved	  from	  the	  resin	  and	  purified	  following	  the	  general	  procedure.	  
Analytical	  UHPLC:	  linear	  gradient	  from	  0%	  to	  100%	  B	  over	  11	  min,	  Rt	  =	  3.25	  min.	  ESI-­‐MS	  for	  [M+	  3H]
+3:	  622.75	  (calculated	  for	  
7:	  622.70).	  Full	  analytical	  data	  for	  this	  compound	  will	  be	  reported	  by	  us	  elsewhere.	  
	  
Ac-­‐(cyclo-­‐14-­‐18)-­‐AARAARAARAARA[KARAD]-­‐NH2	  (8)	  
The	  peptide	  Fmoc-­‐Lys(Mtt)-­‐Ala-­‐Ala-­‐Ala-­‐Asp(OPip)	  was	  assembled	  on	  the	  solid	  support	  on	  a	  Symphony	  synthetizer	  as	  
described	  in	  the	  automated	  general	  procedure.	  The	  cyclization	  step	  was	  carried	  out	  as	  follow:	  first,	  the	  resin	  was	  treated	  with	  
2%	  TFA	  in	  DCM	  (10	  x	  2	  min),	  washed	  with	  DMF	  and	  then	  a	  solution	  of	  PyBOP	  (4	  equiv)	  and	  DIPEA	  (4	  equiv)	  in	  DMF	  was	  added	  
to	  the	  resin	  and	  the	  reaction	  was	  stirred	  overnight.	  After	  washing	  with	  DMF,	  the	  N-­‐terminal	  Fmoc	  group	  was	  removed	  as	  
usual	  and	  the	  peptide	  chain	  was	  further	  elongated.	  Cleavage	  from	  the	  resin	  and	  purification	  followed	  the	  general	  procedure.	  
Analytical	  UHPLC:	  linear	  gradient	  from	  0%	  to	  100%	  B	  over	  8	  min,	  Rt	  =	  2.60	  min.	  ESI-­‐MS	  for	  [M+	  3H]
+3:	  616.70;	  (calculated	  for	  
8:	  616.71).	  ).	  Full	  analytical	  data	  for	  this	  compound	  will	  be	  reported	  by	  us	  elsewhere.	  
	  
Ac-­‐(cyclo-­‐14,18)-­‐AARAARAARAARA[X14-­‐ARA-­‐X18]-­‐NH2,	  hydrocarbon	  linker	  (9)	  
Fmoc-­‐(S)-­‐2-­‐(4-­‐pentenyl)alanine	  (Fmoc-­‐X-­‐OH)	  was	  employed	  for	  incorporation	  of	  non-­‐standard	  amino	  acids	  at	  positions	  14	  
and	  18.	  The	  peptide	  sequence	  Fmoc-­‐X-­‐Ala-­‐Ala-­‐Ala-­‐X	  was	  assembled	  on	  the	  solid	  support	  on	  a	  Symphony	  synthetizer	  as	  
described	  in	  the	  automated	  general	  procedure.	  The	  RCM	  was	  carried	  out	  in	  DCM	  and	  addition	  of	  Grubb’s	  catalyst	  1st	  
generation.	  After	  washing	  with	  DMF,	  the	  N-­‐terminal	  Fmoc	  group	  was	  removed	  as	  usual	  and	  the	  peptide	  chain	  was	  further	  
elongated.	  Cleavage	  from	  the	  resin	  and	  purification	  followed	  the	  general	  procedure.	  
Analytical	  UHPLC:	  linear	  gradient	  from	  0%	  to	  100%	  B	  over	  6	  min,	  Rt	  =	  2.60	  min.	  ESI-­‐MS	  for	  [M+	  3H]
+3:	  624.96	  (calculated	  for	  9:	  
624.94).	  	  
	  







































Fmoc-­‐Lys(N3)-­‐OH	  and	  Fmoc-­‐Pra-­‐OH	  	  were	  employed	  for	  incorporation	  of	  non-­‐standard	  amino	  acids	  at	  positions	  14	  and	  18	  
respectively.	  The	  peptide	  sequence	  Ac-­‐AARAARAARAARA-­‐Lys(N3)-­‐AAA-­‐Pra	  was	  assembled	  on	  the	  solid	  support	  on	  a	  
Symphony	  synthesizer	  as	  described	  in	  the	  automated	  general	  procedure.	  The	  peptide	  was	  cleaved	  from	  the	  resin	  and,	  after	  
freeze-­‐drying,	  submitted	  to	  cyclization.	  The	  crude	  linear	  peptide	  (29mg)	  was	  dissolved	  in	  a	  solution	  of	  H20:tBuOH	  (2:1,	  150	  
mL)	  containing	  CuSO4.5H2O	  (40mg).	  Sodium	  ascorbate	  (33mg)	  was	  added,	  the	  reaction	  mixture	  was	  stirred	  for	  25	  minutes,	  
and	  finally	  quenched	  by	  addition	  of	  TFA	  until	  the	  solution	  was	  clear.	  The	  resulting	  solution	  was	  lyophilised	  and	  the	  cyclic	  
product	  was	  purified	  by	  RP-­‐HPLC.	  	  
Analytical	  HPLC:	  linear	  gradient	  from	  0%	  to	  60%	  B	  over	  20	  min,	  Rt	  =	  13.1	  min.	  ESI-­‐MS	  for	  [M+	  2H]
+2,	  [M+	  3H]+3	  and	  [M+	  4H]+4:	  	  
936.2,	  624.8	  and	  468.8	  respectively;	  (calculated	  for	  9:	  936.0,	  624.4	  and	  468.5	  respectively).	  	  
	  
Circular	  Dichroism	  Spectroscopy	  
Peptide	  solutions	  were	  prepared	  from	  aqueous	  peptide	  stock	  solutions	  of	  accurate	  molecular	  concentrations	  determined	  by	  
NMR.	  The	  final	  concentration	  of	  the	  peptide	  samples	  was	  250	  μM	  in	  a)	  10mM	  phosphate	  buffer	  pH	  7.2;	  or	  b)	  10mM	  
phosphate	  buffer	  pH	  7.2	  in	  50%	  TFE.	  CD	  measurements	  were	  performed	  using	  a	  Jasco	  model	  J-­‐710	  spectropolarimeter	  which	  
was	  routinely	  calibrated	  with	  (1S)-­‐(+)-­‐10-­‐camphorsulfonic	  acid.	  Spectra	  were	  recorded	  at	  room	  temperature	  (298K),	  with	  a	  
0.1	  cm	  Jasco	  quartz	  cell	  over	  the	  wavelength	  range	  260-­‐185	  nm	  at	  50	  nm/min,	  with	  a	  bandwidth	  of	  1.0	  nm,	  response	  time	  of	  
1	  s,	  resolution	  step	  width	  of	  1	  nm	  and	  sensitivity	  of	  20-­‐50	  Mdeg.	  	  Each	  spectrum	  represents	  the	  average	  of	  5	  scans.	  Spectra	  
were	  analysed	  using	  the	  spectral	  analysis	  software	  and	  smoothed	  using	  ‘adaptive	  smoothing’	  function.	  Concentrations	  were	  
determined	  using	  the	  PULCON	  method.6	  NMR	  solutions	  were	  prepared	  with	  540	  µL	  of	  stock	  solution	  and	  60	  µL	  of	  D2O.	  90
o	  
pulses	  were	  accurately	  determined	  and	  then	  1D	  Spectra	  were	  acquired	  using	  the	  standard	  watergate	  sequence	  with	  a	  ns=	  
32-­‐64,	  d1=	  25-­‐35s.	  Spectra	  were	  also	  acquired	  for	  a	  4.76	  mM	  solution	  of	  L-­‐histidine	  as	  the	  reference	  standard.	  The	  fully	  
resolved,	  most	  downfield	  amide	  resonance	  was	  integrated	  and	  used	  to	  calculate	  the	  concentration	  from	  the	  equation:	  
	  
where	  c	  is	  the	  concentration,	  S	  is	  the	  integral(in	  absolute	  units)/number	  of	  protons,	  T	  is	  the	  temperature	  in	  Kelvin,	  θ360	  is	  the	  
360o	  rf	  pulse,	  n	  is	  the	  number	  of	  scans,	  and	  rg	  is	  the	  receiver	  gain	  used	  for	  measuring	  the	  reference	  (R)	  and	  unknown	  (U)	  
samples.	  
	  
Percentage	  Helicity	  of	  peptides	  were	  calculated	  from	  residue-­‐molar	  elipticity	  at	  215	  nm	  (for	  1-­‐6)	  and	  at	  222	  nm	  (for	  longer	  
peptides	  7-­‐10)	  using	  the	  following	  equation:	  




Where	  [θ]max	  ([θ]max	  =	  [θ]∞(n	  –	  x)/n)	  is	  the	  maximum	  theoretical	  mean	  residue	  ellipticity	  for	  a	  helix	  of	  n	  residues,	  [θ]∞	  is	  the	  
mean	  residue	  ellipticity	  of	  an	  infinite	  helix,	  and	  x	  is	  an	  empirical	  constant	  that	  can	  be	  interpreted	  as	  the	  effective	  number	  of	  
amides	  missing	  as	  a	  result	  of	  end	  effects,	  usually	  about	  2.4-­‐4	  (we	  used	  x=3)	  and	  [θ]∞	  =	  (-­‐44000	  +	  250T)	  (T	  is	  temperature	  of	  
the	  peptide	  solution	  in	  ˚C).	  [θ]0	  is	  the	  mean	  residue	  ellipticity	  of	  the	  peptide	  in	  random	  coil	  conformation	  and	  equals	  to	  (2220	  
–	  53T)	  and	  [θ]222	  ([θ]222	  =	  1/n	  .	  [θobs]/(10	  x	  l	  x	  C))	  is	  the	  observed	  residue	  ellipticity	  of	  peptide	  at	  222	  nm.	  Where	  θobs	  =	  
measured	  ellipticity	  in	  mdeg;	  n	  =	  number	  of	  peptide	  residues;	  C	  =	  sample	  concentration	  (mol/L);	  l	  =	  optical	  path	  length	  of	  the	  
cell	  in	  cm.7	  
	  
Proton	  NMR	  Spectroscopy	  
The	  samples	  for	  the	  NMR	  analyses	  of	  1,	  2	  and	  3a	  were	  prepared	  by	  dissolving	  the	  peptide	  (2.2	  mg)	  in	  540	  μL	  H2O	  and	  60	  μL	  
D2O	  at	  pH	  5.0.	  1D	  and	  2D	  
1H-­‐NMR	  spectra	  were	  recorded	  on	  a	  Bruker	  Avance	  DRX-­‐600	  spectrometer.	  2D	  1H-­‐spectra	  were	  
recorded	  in	  phase-­‐sensitive	  mode	  using	  time-­‐proportional	  phase	  incrementation	  for	  quadrature	  detection	  in	  the	  t1	  
dimension.	  	  The	  2D	  experiments	  included	  TOCSY	  (standard	  Bruker	  mlevgpph	  pulse	  program),	  ROESY	  (standard	  Bruker	  
roesygpph	  pulse	  program)	  and	  dqfCOSY	  (standard	  Bruker	  dqfcosygpph	  pulse	  program).	  TOCSY	  spectra	  were	  acquired	  over	  
6887	  Hz	  with	  4096	  complex	  data	  points	  in	  F2,	  512	  increments	  in	  F1	  and	  32	  scans	  per	  increment.	  ROESY	  spectra	  were	  acquired	  
over	  6887	  Hz	  with	  4096	  complex	  data	  points	  in	  F2,	  512	  increments	  in	  F1	  and	  32	  scans	  per	  increment.	  TOCSY	  and	  ROESY	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spectra	  were	  acquired	  with	  several	  isotropic	  mixing	  times	  of	  80,	  100	  ms	  for	  TOCSY	  and	  350	  ms	  for	  ROESY.	  For	  all	  NMR	  
experiments,	  water	  suppression	  was	  achieved	  using	  modified	  WATERGATE.	  For	  1D	  1H	  NMR	  spectra	  acquired	  in	  H2O/D2O	  (9:1),	  
the	  water	  resonance	  was	  suppressed	  by	  low	  power	  irradiation	  during	  the	  relaxation	  delay	  (1.5	  to	  3.0	  s).	  The	  variable	  NMR	  
experiments	  were	  performed	  over	  the	  range	  of	  278-­‐318K.	  Spectra	  were	  processed	  using	  Topspin	  (Bruker,	  Germany)	  software	  
and	  ROE	  intensities	  were	  collected	  manually.	  The	  t1	  dimensions	  of	  all	  2D	  spectra	  were	  zero-­‐filled	  to	  1024	  real	  data	  points	  
with	  90˚	  phase-­‐shifted	  QSINE	  bell	  window	  functions	  applied	  in	  both	  dimensions	  followed	  by	  Fourier	  transformation	  and	  fifth	  
order	  polynomial	  baseline	  correction.	  1H	  chemical	  shifts	  were	  referenced	  to	  DSS	  (δ	  0.00	  ppm)	  in	  water.	  3JNHCHα	  coupling	  
constants	  were	  measured	  from	  1D	  1H	  NMR	  and	  dqf-­‐COSY	  spectra	  using	  XPLOR	  program.	  13C	  spectra	  were	  obtained	  with	  a	  
sweep	  width	  of	  20840	  Hz	  with	  20000-­‐10000	  scans	  and	  65K	  data	  points.	  13C	  NMR	  spectra	  were	  1H-­‐decoupled.	  Phase	  sensitive	  
HSQC	  spectra	  were	  obtained	  with	  900	  increments	  in	  F1,	  2K	  data	  points	  in	  F2	  and	  32	  scans	  per	  increment.	  These	  were	  a	  2-­‐D	  
1H/13C	  correlation	  via	  double	  inept	  transfer	  using	  sensitivity	  improvement	  with	  standard	  Bruker	  pulse	  programs	  of	  invietgssi	  
or	  invietgpsi.	  HMBC	  spectra	  were	  obtained	  with	  1024	  increments	  in	  F1,	  2K	  data	  points	  in	  F2	  and	  32	  scans	  per	  increment	  using	  
a	  standard	  Bruker	  pulse	  program	  inv4gslprnd.	  There	  was	  also	  1H/13C	  correlation	  via	  heteronuclear	  zero	  and	  double	  quantum	  
coherence.	  The	  experiments	  were	  optimized	  on	  long	  range	  couplings	  with	  low-­‐pass	  J-­‐filter	  to	  suppress	  one	  bond	  correlations	  
and	  using	  gradient	  pulses	  for	  selection.	  
	  
Structure	  Calculations	  	  
The	  distance	  restraints	  used	  in	  calculating	  the	  structure	  for	  1,	  2	  and	  3a	  in	  water	  were	  derived	  from	  ROESY	  spectra	  (recorded	  
at	  298K)	  using	  mixing	  time	  of	  350ms	  with	  9	  and	  25	  ROEs	  for	  1	  and	  2	  respectively.	  ROE	  cross-­‐peak	  volumes	  were	  classified	  
manually	  as	  strong	  (upper	  distance	  constraint	  ≤	  2.7Å),	  medium	  (≤	  3.5Å),	  weak	  (≤	  5.0Å)	  and	  very	  weak	  (≤	  6.0Å).	  Standard	  
pseudoatom	  distance	  corrections8	  were	  applied	  for	  non-­‐stereospecifically	  assigned	  protons.	  To	  address	  the	  possibility	  of	  
conformational	  averaging,	  intensities	  were	  classified	  conservatively	  and	  only	  upper	  distance	  limits	  were	  included	  in	  the	  
calculations	  to	  allow	  the	  largest	  possible	  number	  of	  conformers	  to	  fit	  the	  experimental	  data.	  Backbone	  dihedral	  angle	  
restraints	  were	  inferred	  from	  3JNHCHα	  	  coupling	  constants	  in	  1D	  spectra,	  φ	  was	  restrained	  to	  –65	  ±	  30°	  for	  
3JNHCHα	  	  ≤	  6Hz	  and	  to	  -­‐
120±	  30°	  for	  3JNHCHα	  	  ≥	  8Hz.	  	  There	  was	  clearly	  no	  evidence	  at	  all	  for	  cis-­‐amides	  about	  peptide	  bonds	  (i.e.	  no	  CHα-­‐CHα	  (i,	  i+1)	  
ROEs)	  in	  the	  ROESY	  spectra	  (in	  both	  9:1	  H2O/D2O	  and	  100%	  D2O)	  so	  all	  ψ-­‐angles	  were	  set	  to	  trans	  (ψ	  =	  180˚).	  Starting	  
structures	  with	  randomised	  φ	  and	  ψ	  angles	  and	  extended	  side	  chains	  were	  generated	  using	  an	  ab	  initio	  simulated	  annealing	  
protocol.	  The	  calculations	  were	  performed	  using	  the	  standard	  forcefield	  parameter	  set	  (PARALLHDG5.2.PRO)	  and	  topology	  
file	  (TOPALLHDG5.2.PRO)	  in	  XPLOR-­‐NIH	  with	  in	  house	  modifications	  to	  generated	  lactam	  bridges	  between	  lysine	  and	  aspartic	  
acid	  residues.	  Refinement	  of	  structures	  was	  achieved	  using	  the	  conjugate	  gradient	  Powell	  algorithm	  with	  4000	  cycles	  of	  
energy	  minimisation	  and	  a	  refined	  forcefield	  based	  on	  the	  program	  CHARMm.7	  Structures	  were	  visualised	  with	  InsightII	  and	  
analysed	  for	  distance	  (>0.2Å)	  and	  dihedral	  angle	  (>5o)	  violations	  using	  noe.inp	  files.	  Final	  structures	  contained	  no	  distance	  
violations	  (>0.2Å)	  or	  angle	  violations	  (>5o).	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Figure	  S1.	  %	  Helicity	  based	  on	  molar	  elipticity	  at	  215	  nm	  at	  298K	  in	  10	  mM	  phosphate	  buffer	  or	  in	  50%	  TFE/10	  mM	  PBS	  pH	  
7.2.	  *	  The	  CD	  fingerprint	  of	  m-­‐xylene	  staple	  4	  in	  50%	  TFE/10mM	  PBS	  pH	  7.2	  is	  of	  an	  unknown	  configuration	  and	  %	  helicity	  






Figure	  S2.	  Temperature	  dependence	  of	  the	  amide	  NH	  chemical	  shifts	  for	  1	  in	  H2O/D2O	  (9:1).	  Line	  slopes	  indicating	  
temperature	  coefficients	  (Δδ/T)	  for	  each	  residue	  are	  shown	  in	  brackets.	  	  ●	  Lys	  1	  [7.4	  ppb/K],	  ■	  Ala	  2	  [3.9	  ppb/K],	  ▲	  Ala	  3	  
[7.7	  ppb/K],	  ▼	  Ala	  4	  [2.6	  ppb/K],	  ¿	  Asp	  5	  [4.8	  ppb/K],	  	  Amide	  1	  [8.7	  ppb/K],	  £	  Amide	  2	  [2.1	  ppb/K],	  r	  side-­‐chain	  lactam	  

























Figure	  S3.	  Temperature	  dependence	  of	  the	  amide	  NH	  chemical	  shifts	  for	  2	  in	  H2O/ACN-­‐d3	  (1:1).	  Line	  slopes	  indicating	  
temperature	  coefficients	  (Δδ/T)	  for	  each	  residue	  are	  shown	  in	  brackets.	  	  ●	  X	  1	  [7.0	  ppb/K],	  ■	  Ala	  2	  [6.3	  ppb/K],	  ▲	  Ala	  3	  [0.7	  
ppb/K],	  ▼	  Ala	  4	  [0.3	  ppb/K],	  ¿	  Asp	  5	  [4.0	  ppb/K],	  	  Amide	  1	  [1.3	  ppb/K],	  £	  Amide	  2	  [6.0	  ppb/K].	  	  






















Figure	  S4.	  Temperature	  dependence	  of	  the	  amide	  NH	  chemical	  shifts	  for	  3a	  in	  H2O/ACN-­‐d3	  (1:1).	  Line	  slopes	  indicating	  
temperature	  coefficients	  (Δδ/T)	  for	  each	  residue	  are	  shown	  in	  brackets.	  	  ●	  X	  1	  [7.0	  ppb/K],	  ■	  Ala	  2	  [4.0	  ppb/K],	  ▲	  Ala	  3	  [6.0	  







Fig.	  S5.	  Differences	  between	  observed	  chemical	  shift	  and	  random	  coil	  values	  (Δδ 	  =	  δ 	  -­‐	  δ random*)	  for	  peptides	  1,	  2	  and	  3a	  in	  
H2O/D2O	  (9:1).	  Negative	  values	  >	  -­‐0.1ppm	  indicate	  upfield	  shifts	  that	  are	  typically	  observed	  for	  helical	  residues.	  This	  figure	  







A	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  B	  




























































Figure	  S6.	  Variable	  temperature	  (0C)	  circular	  dichroism	  spectra	  of	  (A)	  2	  and	  (B)	  3a	  in	  10mM	  phosphate	  buffer	  (pH	  7.4)	  









































Figure	  S7.	  H-­‐D	  exchange	  rate	  of	  the	  amides	  NHs	  for	  1	  (A)	  and	  2	  (B)	  in	  DMSO-­‐d6	  at	  298	  K.	  The	  fast	  NH	  exchange	  rate	  is	  similar	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Figure	  S8.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  1a.	  
	  
	  
Figure	  S9.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  1b.	  
	  
	  
Figure	  S10.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  1c.	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Figure	  S11.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  2.	  
	  
Current Chromatogram(s)
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Figure	  S12.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  2a.	  
	  
Current Chromatogram(s)
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Figure	  S14.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  3a.	  
	  
Current Chromatogram(s)
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Figure	  S15.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  3b.	  
	  
Current Chromatogram(s)
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Figure	  S16.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  3c.	  	  
Triazole	  	  3a	  

















 DAD1 A, Sig=214,8 Ref=360,100 (ALINE\18AUG13B 2013-08-23 11-02-57\B39B-1.D)
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  Figure	  S17.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  3d	  	  
	  
	  
Figure	  S18.	  UHPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  4.	  	  
	  
Current Chromatogram(s)
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  Figure	  S19.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  6a.	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Figure	  S20.	  HPLC	  chromatogram	  of	  the	  pure	  cyclopentapeptide	  6b.	  	  
	  
	  
Figure	  S21.	  UHPLC	  chromatogram	  of	  the	  pure	  18mer	  9.	  	  
	  
Current Chromatogram(s)
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  Figure	  S22.	  HPLC	  chromatogram	  of	  the	  pure	  18mer	  10.	  
Thioether	  	  6b	  




ANALYTICAL	  DATA	  (NMR-­‐1D)	  
	  
	  
Figure	  S23.	  600MHz	  1H	  NMR	  spectrum	  of	  1a	  in	  H2O/D2O	  (9:1)	  at	  298K.	  
	  
	  
































Figure	  S31.	  600MHz	  1H	  NMR	  spectrum	  of	  3d	  in	  H2O/D2O	  (9:1)	  at	  298K.	  
	  
	  




Figure	  S33.	  600MHz	  1H	  NMR	  spectrum	  of	  5	  in	  H2O/D2O	  (9:1)	  at	  298K.	  
	  
	  

















































Figure	  S40.	  600MHz	  TOCSY	  fingerprint	  region	  of	  2	  in	  H2O/CD3CN	  (1:1)	  at	  298K.	  Connectivity	  of	  the	  NH,	  Cα,	  Cβ	  protons	  for	  the	  
peptide	  is	  shown	  by	  the	  solid	  line.	  
	  
	  
Figure	  S41.	  Magnified	  NH-­‐CHα	  region	  from	  the	  600MHz	  ROESY	  spectrum	  of	  2	  in	  H2O/CD3CN	  (1:1)	  at	  298K.	  Sequential	  






Figure	  S42.	  600MHz	  TOCSY	  fingerprint	  region	  of	  3a	  in	  H2O/D2O	  (9:1)	  at	  298K.	  Connectivity	  of	  the	  NH,	  Cα,	  Cβ	  protons	  for	  the	  




Figure	  S43.	  Magnified	  NH-­‐CHα	  region	  from	  the	  600MHz	  ROESY	  spectrum	  of	  3a	  in	  H2O/D2O	  (9:1)	  at	  298K.	  Sequential	  
















3JNHCHα	  (Hz)	   Δδ/T	  (ppb/K)	  
1	   2	   3a	   1	   2	   3a	  
X1	   3.6	   *	   4.7	   7.4	   7.0	   6.8	  
A2	   3.7	   2.8	   4.4	   3.9	   6.5	   4.0	  
A3	   5.2	   6.1	   5.8	   7.7	   0.6	   5.8	  
A4	   4.6	   7.7	   5.3	   2.6	   0.6	   2.9	  
X5	   7.0	   *	   6.8	   4.8	   4.0	   2.2	  
NH2T	   *	   *	   	   2.1/8.7	   1.3/6.0	   1.5/7.0	  
NH	  lactam	   7.8	   	   	   9.3	   	   	  
	  
*	  singlet	  peaks	  
	  
	  
Table	  S2.	  1H	  NMR	  resonance	  assignments	  and	  chemical	  shifts	  (δ	  ppm)	  for	  2	  in	  H2O/ACN	  (1:1)	  at	  298K.	  
Residue	   δ	  (ppm)	  
NH	   Hα 	   Hβ 	   Other	  
Ac-­‐S	  2	   8.02	   n/a	   1.57,	  1.24	   γCH2	  1.69,	  1.36;	  δCH2	  2.01,	  1.69;	  	  	  	  	  εCH1	  
5.40;	  Acetyl	  Cα	  1.96	  
Ala	  3	   8.36	   3.92	   1.36	   	  
Ala	  4	   7.64	   4.02	   1.35	   	  
Ala	  5	   7.30	   4.13	   1.36	   	  
S	  6	  –NH2	   7.53	   n/a	   1.35,	  1.13	   γCH2	  1.69,	  1.57;	  δCH2	  1.89,	  1.57;	  	  	  	  	  εCH1	  
5.32;	  NH1	  6.83;	  NH2	  6.50	  
	  
Table	  S3.	  ROE-­‐derived	  distances,	  3JNH-­‐CHα	  derived	  j-­‐angle	  restraints	  and	  hydrogen-­‐bond	  restraints	  used	  for	  calculating	  the	  
solution	  structure	  of	  2	  in	  H2O/ACN	  (1:1)	  at	  298K.	  
Acetyl1	  Hα*	   S2	  HN	   4.2	  Å;	  Strong+	  1.5Å	  correction	  
Acetyl1	  Hα*	   Ala3	  HN	   6.0	  Å;	  Very	  Weak,	  no	  correction	  
Acetyl1	  Hα*	   Ala4	  HN	   6.0	  Å;	  Very	  Weak,	  no	  correction	  
Acetyl1	  Hα*	   Ala5	  HN	   6.0	  Å;	  Very	  Weak,	  no	  correction	  
S2	  HN	   Ala3	  HN	   5.0	  Å;	  Weak	  
Ala3	  Hα	   Ala4	  HN	   5.0	  Å;	  Weak	  
Ala3	  Hα	   Ala5	  HN	   6.0	  Å;	  Very	  Weak	  
Ala3	  Hα	   Ala6	  HN	   5.0	  Å;	  Weak	  
Ala3	  Hα	   S6	  H1	   6.0	  Å;	  Very	  Weak	  
Ala3	  Hα	   S6	  H2	   6.0	  Å;	  Very	  Weak	  
Ala3	  HN	   Ala4	  HN	   3.5	  Å;	  Medium	  
Ala4	  Hα	   Ala5	  HN	   5.0	  Å;	  Weak	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Ala4	  Hα	   S6	  HN	   6.0	  Å;	  Very	  Weak	  
Ala4	  Hα	   S6	  H1	   6.0	  Å;	  Very	  Weak	  
Ala4	  Hα	   S6	  H2	   6.0	  Å;	  Very	  Weak	  
Ala4	  HN	   Ala5	  HN	   3.5	  Å;	  Medium	  
Ala5	  Hα	   S6	  HN	   5.0	  Å;	  Weak	  
Ala5	  Hα	   S6	  H1	   6.0	  Å;	  Very	  Weak	  
Ala5	  Hα	   S6	  H2	   6.0	  Å;	  Very	  Weak	  
Ala5	  HN	   S6	  HN	   3.5	  Å;	  Medium	  
S6	  HN	   S6	  H1	   3.5	  Å;	  Medium	  
S6	  HN	   S6	  H2	   6.0	  Å;	  Very	  Weak	  
	  
ϕ-­‐angle	  restraints	  
Residue	   3JNH-­‐CHα	  (Hz)	   ϕ -­‐dihedral	  angle	  restraint	  
Ala3	   2.8	   -­‐60°±	  30°	  
Ala4	   6.1	   -­‐60°±	  30°	  
	  
Hydrogen-­‐bond	  restraints	  
Donor	   Acceptor	   H-­‐O	  Distance	   N-­‐O	  Distance	  
S6	  H1	   Ala3	  O	   1.88[-­‐.3	  Å,+.42	  Å]	   2.88	  [-­‐.3	  Å,+.32	  Å]	  
S6	  NH	   S2	  O	   1.88[-­‐.3	  Å,+.42	  Å]	   2.88	  [-­‐.3	  Å,+.32	  Å]	  
Ala5	  NH	   Acetyl1	  O	   1.88[-­‐.3	  Å,+.42	  Å]	   2.88	  [-­‐.3	  Å,+.32	  Å]	  
*	  Represents	  protons	  that	  were	  not	  stereospecifically	  assigned	  and	  whose	  distance	  restraints	  were	  adjusted	  with	  standard	  





Table	  S4.	  1H	  NMR	  resonance	  assignments	  and	  chemical	  shifts	  (δ	  ppm)	  for	  3a	  in	  H2O/D2O	  (9:1)	  at	  298K.	  
Residue	   δ	  (ppm)	  
NH	   Hα 	   Hβ 	   Other	  
Ac-­‐X	  2	   8.14	   4.00	   1.67	   γCH2	  1.37,	  1.00;	  δCH2	  1.83,	  1.74;	  	  	  	  	  εCH2	  
4.37,	  4.25;	  Acetyl	  Cα	  1.92	  
Ala	  3	   8.21	   3.88	   1.28	   	  
Ala	  4	   7.62	   4.13	   1.27	   	  
Ala	  5	   7.87	   4.13	   1.33	   	  
X	  6	  –NH2	   7.88	   4.59	   3.26;	  3.13	   δCH	  7.74;	  NH1	  7.29;	  NH2	  7.14	  
	  
	  
Table	  S5.	  ROE-­‐derived	  distances,	  3JNH-­‐CHα	  derived	  j-­‐angle	  restraints	  and	  hydrogen-­‐bond	  restraints	  used	  for	  calculating	  the	  
solution	  structure	  of	  3a	  in	  H2O/D2O	  (9:1)	  at	  298K.	  
Acetyl1	  Hα*	   X2	  HN	   5.0	  Å;	  Medium	  +	  1.5Å	  correction	  
Acetyl1	  Hα*	   Ala3	  HN	   6.0	  Å;	  Very	  Weak,	  no	  correction	  
Acetyl1	  Hα*	   Ala4	  HN	   6.0	  Å;	  Very	  Weak,	  no	  correction	  
X2	  Hα	   Ala4	  HN	   6.0	  Å;	  Very	  Weak	  
X2	  HN	   Ala5	  HN	   5.0	  Å;	  Weak	  
X2	  Hα	   Ala5	  Hβ*	   5.0	  Å;	  Strong	  +	  1.5Å	  correction	  
X2	  HE*	   X2	  HG*	   6.0	  Å;	  Weak	  (1.0Å	  correction)	  
X2	  Hα	   Ala3	  HN	   2.7	  Å;	  Strong	  
X2	  Hε*	   X6	  Hδ2	   5.0	  Å;	  Weak	  
X2	  Hβ*	   Ala3	  HN	   6.0	  Å;	  Weak	  (1.0Å	  correction)	  
Ala3	  HN	   Ala4	  HN	   3.5	  Å;	  Medium	  
Ala3	  Hα	   Ala4	  HN	   3.5	  Å;	  Medium	  
Ala3	  Hα	   Ala5	  HN	   6.0	  Å;	  Very	  Weak	  
Ala3	  Hα	   X6	  Hβ1	   6.0	  Å;	  Very	  Weak	  
Ala4	  Hα	   Ala5	  HN	   2.7	  Å;	  Strong	  
Ala4	  Hα	   X6	  HN	   6.0	  Å;	  Very	  Weak	  
Ala4	  Hα	   X6	  H1	   6.0	  Å;	  Very	  Weak	  
Ala4	  Hβ*	   Ala5	  HN	   6.0	  Å;	  Very	  Weak	  
Ala4	  HN	   Ala5	  HN	   3.5	  Å;	  Medium	  
Ala5	  Hα	   X6	  HN	   6.0	  Å;	  Very	  Weak	  
Ala5	  Hα	   Ala2	  Hγ*	   6.0	  Å;	  Very	  Weak	  
Ala5	  Hβ*	   X6	  HN	   6.0	  Å;	  Very	  Weak	  
X6	  Hα	   X6	  H1	   3.5	  Å;	  Medium	  
X6	  Hα	   X6	  H2	   6.0	  Å;	  Very	  Weak	  
X6	  HN	   X6	  H1	   5.0	  Å;	  Weak	  
X6	  HN	   X6	  H2	   6.0	  Å;	  Very	  Weak	  
X6	  Hβ*	   X6	  Hδ2	   5.0	  Å;	  Weak	  
X6	  Hβ1	   X6	  H1	   5.0	  Å;	  Weak	  
X6	  Hβ2	   X6	  H1	   6.0	  Å;	  Very	  Weak	  
X6	  HN	   X6	  Hβ1	   5.0	  Å;	  Weak	  
X6	  HN	   X6	  Hβ2	   6.0	  Å;	  Very	  Weak	  
X6	  Hα	   X6	  Hβ1	   3.5	  Å;	  Medium	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Residue	   3JNH-­‐CHα	  (Hz)	   ϕ-­‐dihedral	  angle	  restraint	  
X2	   4.7	   -­‐60°±	  30°	  
Ala3	   4.4	   -­‐60°±	  30°	  
Ala4	   5.8	   -­‐60°±	  30°	  




Donor	   Acceptor	   H-­‐O	  Distance	   N-­‐O	  Distance	  
X6	  H1	   Ala3	  O	   1.88[-­‐.3	  Å,+.42	  Å]	   2.88	  [-­‐.3	  Å,+.42	  Å]	  
X6	  NH	   X2	  O	   1.88[-­‐.3	  Å,+.42	  Å]	   2.88	  [-­‐.3	  Å,+.42	  Å]	  
Ala5	  NH	   Acetyl1	  O	   1.88[-­‐.3	  Å,+.42	  Å]	   2.88	  [-­‐.3	  Å,+.42	  Å]	  
*	  Represents	  protons	  that	  were	  not	  stereospecifically	  assigned	  and	  whose	  distance	  restraints	  were	  adjusted	  with	  standard	  
pseudoatom	  corrections	  (Wuthrich,	  K.;	  Billeter,	  M.;	  Braun,	  W.	  J.	  Mol.	  Biol.	  1983,	  169,	  949).	  
	  
	  
 
